Hypertension Diagnostics, Inc. Logo

Hypertension Diagnostics, Inc.

HDII

(2.0)
Stock Price

0,00 USD

-9.81% ROA

0% ROE

0x PER

Market Cap.

136.814,00 USD

-98.6% DER

0% Yield

0% NPM

Hypertension Diagnostics, Inc. Stock Analysis

Hypertension Diagnostics, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Hypertension Diagnostics, Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (0x), the stock offers substantial upside potential at a bargain price.

2 DER

The stock has a minimal amount of debt (-99%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 Net Profit Growth

This company has consistently achieved strong net profit growth over the past five years, demonstrating a solid financial performance and making it an appealing investment option.

4 ROE

ROE in an average range (2.67%) suggests satisfactory profitability and decent utilization of shareholders' equity.

5 Revenue Growth

With a track record of continuous revenue growth in the last three years, this company offers a promising investment opportunity

6 ROA

The stock's ROA (-9.81%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

7 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

8 Graham Number

The Graham number calculation reveals that this company's stock price is potentially inflated, implying that it may not be a desirable investment option.

9 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

10 Dividend

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

11 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is overpriced (0), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

Hypertension Diagnostics, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Hypertension Diagnostics, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Hold

Hypertension Diagnostics, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Hypertension Diagnostics, Inc. Revenue
Year Revenue Growth
1998 100.000
1999 400.000 75%
2000 423.490 5.55%
2001 2.047.304 79.31%
2002 549.198 -272.78%
2003 775.336 29.17%
2004 1.074.515 27.84%
2005 1.182.005 9.09%
2006 1.789.546 33.95%
2007 1.878.840 4.75%
2008 554.454 -238.86%
2009 503.175 -10.19%
2010 1.383.669 63.63%
2011 1.389.181 0.4%
2012 3.157.747 56.01%
2016 3.567.059 11.47%
2017 3.677.782 3.01%
2018 3.792.106 3.01%
2019 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Hypertension Diagnostics, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1998 300.000
1999 600.000 50%
2000 430.019 -39.53%
2001 315.017 -36.51%
2002 40.827 -671.59%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Hypertension Diagnostics, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1998 0
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 999.119 100%
2012 1.190.606 16.08%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Hypertension Diagnostics, Inc. EBITDA
Year EBITDA Growth
1998 -1.200.000
1999 -2.600.000 53.85%
2000 -3.532.265 26.39%
2001 -2.335.011 -51.27%
2002 -5.686.301 58.94%
2003 -3.198.508 -77.78%
2004 -1.578.503 -102.63%
2005 -1.324.386 -19.19%
2006 -1.197.218 -10.62%
2007 -522.890 -128.96%
2008 -726.394 28.02%
2009 -252.436 -187.75%
2010 -1.036.648 75.65%
2011 -1.041.627 0.48%
2012 -1.228.902 15.24%
2016 -431.530 -184.78%
2017 -178.800 -141.35%
2018 72.290 347.34%
2019 0 0%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Hypertension Diagnostics, Inc. Gross Profit
Year Gross Profit Growth
1998 100.000
1999 300.000 66.67%
2000 410.518 26.92%
2001 1.580.991 74.03%
2002 447.586 -253.23%
2003 -206.521 316.73%
2004 898.611 122.98%
2005 997.021 9.87%
2006 1.699.099 41.32%
2007 1.812.427 6.25%
2008 510.125 -255.29%
2009 492.184 -3.65%
2010 1.363.734 63.91%
2011 1.113.333 -22.49%
2012 -111.854 1095.34%
2016 551.189 120.29%
2017 752.388 26.74%
2018 954.474 21.17%
2019 0 0%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Hypertension Diagnostics, Inc. Net Profit
Year Net Profit Growth
1998 -1.100.000
1999 -2.200.000 50%
2000 -3.324.307 33.82%
2001 -2.254.851 -47.43%
2002 -6.369.666 64.6%
2003 -3.802.381 -67.52%
2004 -1.839.949 -106.66%
2005 -1.455.228 -26.44%
2006 -1.272.742 -14.34%
2007 -504.011 -152.52%
2008 -703.837 28.39%
2009 -248.440 -183.3%
2010 -989.759 74.9%
2011 406.312 343.6%
2012 -1.263.247 132.16%
2016 -621.711 -103.19%
2017 -368.611 -68.66%
2018 -125.388 -193.98%
2019 0 0%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Hypertension Diagnostics, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1998 -1
1999 0 0%
2000 -1 0%
2001 0 0%
2002 -1 100%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Hypertension Diagnostics, Inc. Free Cashflow
Year Free Cashflow Growth
1998 -1.200.000
1999 -2.700.000 55.56%
2000 -3.794.704 28.85%
2001 -2.234.044 -69.86%
2002 -4.103.423 45.56%
2003 -1.791.303 -129.07%
2004 -1.479.380 -21.08%
2005 -882.529 -67.63%
2006 -776.928 -13.59%
2007 -308.380 -151.94%
2008 -294.764 -4.62%
2009 -383.950 23.23%
2010 279.080 237.58%
2011 -204.767 236.29%
2012 -1.856.154 88.97%
2016 -386.897 -379.75%
2017 -87.952 -339.9%
2018 -391.389 77.53%
2019 0 0%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Hypertension Diagnostics, Inc. Operating Cashflow
Year Operating Cashflow Growth
1998 -1.100.000
1999 -2.400.000 54.17%
2000 -3.717.528 35.44%
2001 -2.058.280 -80.61%
2002 -4.095.690 49.75%
2003 -1.791.303 -128.64%
2004 -1.474.189 -21.51%
2005 -848.837 -73.67%
2006 -775.875 -9.4%
2007 -303.094 -155.98%
2008 -294.764 -2.83%
2009 -383.950 23.23%
2010 279.080 237.58%
2011 -204.767 236.29%
2012 -1.225.629 83.29%
2016 -384.938 -218.4%
2017 -85.919 -348.02%
2018 -389.278 77.93%
2019 0 0%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Hypertension Diagnostics, Inc. Capital Expenditure
Year Capital Expenditure Growth
1998 100.000
1999 300.000 66.67%
2000 77.176 -288.72%
2001 175.764 56.09%
2002 7.733 -2172.91%
2003 0 0%
2004 5.191 100%
2005 33.692 84.59%
2006 1.053 -3099.62%
2007 5.286 80.08%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 630.525 100%
2016 1.959 -32086.06%
2017 2.033 3.64%
2018 2.111 3.69%
2019 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Hypertension Diagnostics, Inc. Equity
Year Equity Growth
1998 1.400.000
1999 8.500.000 83.53%
2000 5.365.183 -58.43%
2001 5.333.785 -0.59%
2002 2.501.090 -113.26%
2003 122.355 -1944.13%
2004 1.607.386 92.39%
2005 1.603.537 -0.24%
2006 1.840.414 12.87%
2007 1.426.143 -29.05%
2008 816.981 -74.56%
2009 660.041 -23.78%
2010 -146.818 549.56%
2011 419.363 135.01%
2012 -288.669 245.27%
2016 -4.257.777 93.22%
2017 -4.626.388 7.97%
2018 -4.751.776 2.64%
2019 -4.751.776 0%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Hypertension Diagnostics, Inc. Assets
Year Assets Growth
1998 1.600.000
1999 8.700.000 81.61%
2000 5.786.096 -50.36%
2001 5.813.872 0.48%
2002 4.305.963 -35.02%
2003 1.154.904 -272.84%
2004 2.243.906 48.53%
2005 2.193.866 -2.28%
2006 2.345.949 6.48%
2007 2.020.385 -16.11%
2008 1.427.786 -41.5%
2009 1.032.787 -38.25%
2010 1.546.580 33.22%
2011 1.286.008 -20.26%
2012 1.305.813 1.52%
2016 1.402.312 6.88%
2017 1.489.092 5.83%
2018 1.277.829 -16.53%
2019 1.277.829 0%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Hypertension Diagnostics, Inc. Liabilities
Year Liabilities Growth
1998 200.000
1999 200.000 0%
2000 420.913 52.48%
2001 480.087 12.33%
2002 1.804.873 73.4%
2003 1.032.549 -74.8%
2004 636.520 -62.22%
2005 590.329 -7.82%
2006 505.535 -16.77%
2007 594.242 14.93%
2008 610.805 2.71%
2009 372.746 -63.87%
2010 1.693.398 77.99%
2011 866.645 -95.4%
2012 1.594.482 45.65%
2016 5.660.089 71.83%
2017 6.115.480 7.45%
2018 6.029.605 -1.42%
2019 6.029.605 0%

Hypertension Diagnostics, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
0
Price to Earning Ratio
0x
Price To Sales Ratio
0.04x
POCF Ratio
0
PFCF Ratio
-0.35
Price to Book Ratio
0
EV to Sales
1.25
EV Over EBITDA
65.51
EV to Operating CashFlow
-12.17
EV to FreeCashFlow
-12.1
Earnings Yield
0
FreeCashFlow Yield
-2.86
Market Cap
0,00 Bil.
Enterprise Value
0,00 Bil.
Graham Number
0
Graham NetNet
0

Income Statement Metrics

Net Income per Share
0
Income Quality
3.1
ROE
0.03
Return On Assets
0
Return On Capital Employed
0
Net Income per EBT
0
EBT Per Ebit
0
Ebit per Revenue
0
Effective Tax Rate
0

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0
Operating Profit Margin
0
Pretax Profit Margin
0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0
Free CashFlow per Share
0
Capex to Operating CashFlow
0.01
Capex to Revenue
-0
Capex to Depreciation
-0.06
Return on Invested Capital
5.72
Return on Tangible Assets
-0.1
Days Sales Outstanding
37.34
Days Payables Outstanding
57.32
Days of Inventory on Hand
24.37
Receivables Turnover
9.78
Payables Turnover
6.37
Inventory Turnover
14.98
Capex per Share
0

Balance Sheet

Cash per Share
0,00
Book Value per Share
0,00
Tangible Book Value per Share
0
Shareholders Equity per Share
0
Interest Debt per Share
0
Debt to Equity
-0.99
Debt to Assets
3.67
Net Debt to EBITDA
63.62
Current Ratio
0.53
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
-0,01 Bil.
Invested Capital
-0.99
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
187964
Debt to Market Cap
34.25

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Hypertension Diagnostics, Inc. Dividends
Year Dividends Growth

Hypertension Diagnostics, Inc. Profile

About Hypertension Diagnostics, Inc.

Hypertension Diagnostics, Inc. designs, develops, manufactures, and markets proprietary noninvasive medical devices that detect subtle changes in the elasticity of arteries in the United States and internationally. It offers CVProfilor, which allows a physician to non-invasively assess the elasticity of small and large arteries, of which small artery elasticity is the earliest and sensitive marker of cardiovascular disease. The company offers CVProfilor DO-2020, which provides a patient's arterial elasticity indices used in the assessment for underlying vascular disease; CVProfilor MD-3000 that offers a sensitive and specific guide to the presence of blood vessel disease; and HD/PulseWave CR-2000 research cardiovascular profiling system, which provides researchers and scientists with a non-invasive means to assess arterial elasticity in support of human research in various areas. Its products collect 30 seconds of blood pressure waveform data, perform an analysis of the digitized blood pressure waveforms, and generate a CVProfile report that contains information on blood pressure, heart rate, pulse pressure, body surface area, body mass index, and C1-large and C2-small artery elasticity indices. The company sells its products to primary care physicians, cardiologists, health care professionals, trained medical personnel, research investigators at academic medical research centers, government institutes, cardiovascular specialists, and pharmaceutical firms. It markets its products through a representative organization in the United States. Hypertension Diagnostics, Inc. was founded in 1988 and is based in Richmond Hill, Canada.

CEO
Liangjian Peng
Employee
3
Address
550 Highway 7 East
Richmond Hill, L4B 3Z4

Hypertension Diagnostics, Inc. Executives & BODs

Hypertension Diagnostics, Inc. Executives & BODs
# Name Age
1 Liangjian Peng
Chief Executive Officer
70

Hypertension Diagnostics, Inc. Competitors